Literature DB >> 23523131

Induction of pregnant women onto opioid-agonist maintenance medication: an analysis of withdrawal symptoms and study retention.

Amber M Holbrook1, Hendree E Jones, Sarah H Heil, Peter R Martin, Susan M Stine, Gabriele Fischer, Mara G Coyle, Karol Kaltenbach.   

Abstract

BACKGROUND: Induction onto buprenorphine during pregnancy may be more challenging than induction onto methadone. This study explores factors predicting withdrawal intensities and compares trajectories of withdrawal during the induction phase between opioid-dependent women randomly assigned to methadone or buprenorphine.
METHODS: A secondary analysis was conducted on data from 175 opioid-dependent pregnant women inducted onto buprenorphine or methadone subsequent to stabilization on morphine sulfate. ANOVA analyses were conducted to determine differences between mean peak CINA scores by medication and completion status. General linear mixed models were fitted to compare trajectories of CINA scores between methadone and buprenorphine conditions, and between study dropouts and completers within the buprenorphine condition.
RESULTS: Both buprenorphine and methadone patients experienced withdrawal categorized as minimal by the CINA scoring system. Significant differences in mean peak CINA scores for the first 72 hours of induction were found between the methadone (4.5; SD=0.4) and buprenorphine conditions (6.9; SD=0.4), with buprenorphine patients exhibiting higher mean peak CINA scores [F (3, 165)=9.70, p<0.001]. The trajectory of CINA scores showed buprenorphine patients exhibiting a sharper increase in mean CINA scores than methadone patients [F (1, 233)=8.70, p=0.004]. There were no differences in mean peak CINA scores [F (3, 77)=0.08, p=0.52] or in trajectory of CINA scores [F (1, 166)=0.42, p=0.52] between buprenorphine study dropouts and completers.
CONCLUSION: While mean peak CINA score was significantly higher in the buprenorphine condition than the methadone condition, neither medication condition experienced substantial withdrawal symptoms. Further research on factors related to successful induction to buprenorphine treatment in pregnant women is needed.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Buprenorphine induction; CINA; Methodone induction; Opioid dependence; Opioid withdrawal; Pregnancy

Mesh:

Substances:

Year:  2013        PMID: 23523131      PMCID: PMC3732530          DOI: 10.1016/j.drugalcdep.2013.02.031

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  25 in total

1.  Transplacental transfer and metabolism of buprenorphine.

Authors:  Tatiana Nanovskaya; Sujal Deshmukh; Monica Brooks; Mahmoud S Ahmed
Journal:  J Pharmacol Exp Ther       Date:  2002-01       Impact factor: 4.030

2.  Assessment of opioid dependence with naloxone.

Authors:  J E Peachey; H Lei
Journal:  Br J Addict       Date:  1988-02

3.  Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.

Authors:  D R Jasinski; J S Pevnick; J D Griffith
Journal:  Arch Gen Psychiatry       Date:  1978-04

4.  Buprenorphine versus methadone maintenance for the treatment of opioid dependence.

Authors:  G Fischer; W Gombas; H Eder; R Jagsch; A Peternell; G Stühlinger; L Pezawas; H N Aschauer; S Kasper
Journal:  Addiction       Date:  1999-09       Impact factor: 6.526

5.  Buprenorphine treatment of pregnant opioid--dependent women: maternal and neonatal outcomes.

Authors:  R E Johnson; H E Jones; D R Jasinski; D S Svikis; N A Haug; L M Jansson; W B Kissin; G Alpan; M E Lantz; E J Cone; D G Wilkins; A S Golden; G R Huggins; B M Lester
Journal:  Drug Alcohol Depend       Date:  2001-06-01       Impact factor: 4.492

6.  Double-blind randomized trial of buprenorphine and methadone in opiate dependence.

Authors:  S Petitjean; R Stohler; J J Déglon; S Livoti; D Waldvogel; C Uehlinger; D Ladewig
Journal:  Drug Alcohol Depend       Date:  2001-03-01       Impact factor: 4.492

7.  French field experience with buprenorphine.

Authors:  Marc Auriacombe; Mélina Fatséas; Jacques Dubernet; Jean-Pierre Daulouède; Jean Tignol
Journal:  Am J Addict       Date:  2004

8.  Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates.

Authors:  Diann E Gaalema; Teresa Linares Scott; Sarah H Heil; Mara G Coyle; Karol Kaltenbach; Gary J Badger; Amelia M Arria; Susan M Stine; Peter R Martin; Hendrée E Jones
Journal:  Addiction       Date:  2012-11       Impact factor: 6.526

9.  Heroin detoxification with buprenorphine on an inpatient psychiatric unit.

Authors:  Bethany A DiPaula; Robert Schwartz; Ivan D Montoya; David Barrett; Cecilia Tang
Journal:  J Subst Abuse Treat       Date:  2002-10

10.  Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients.

Authors:  Richard P Mattick; Robert Ali; Jason M White; Susannah O'Brien; Seija Wolk; Cath Danz
Journal:  Addiction       Date:  2003-04       Impact factor: 6.526

View more
  8 in total

Review 1.  Pharmacological Management of Opioid Use Disorder in Pregnant Women.

Authors:  Christine M Wilder; Theresa Winhusen
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

2.  Clinical care for opioid-using pregnant and postpartum women: the role of obstetric providers.

Authors:  Hendrée E Jones; Krisanna Deppen; Mark L Hudak; Lisa Leffert; Carol McClelland; Leyla Sahin; Jacquelyn Starer; Mishka Terplan; John M Thorp; James Walsh; Andreea A Creanga
Journal:  Am J Obstet Gynecol       Date:  2013-10-10       Impact factor: 8.661

Review 3.  The opioid epidemic and neonatal abstinence syndrome in the USA: a review of the continuum of care.

Authors:  Jason R Pryor; Faouzi I Maalouf; Elizabeth E Krans; Robert E Schumacher; William O Cooper; Stephen W Patrick
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2017-01-10       Impact factor: 5.747

4.  Caring for Opioid-dependent Pregnant Women: Prenatal and Postpartum Care Considerations.

Authors:  Elizabeth E Krans; Gerald Cochran; Debra L Bogen
Journal:  Clin Obstet Gynecol       Date:  2015-06       Impact factor: 2.190

Review 5.  Perinatal Opioid Use Disorder Research, Race, and Racism: A Scoping Review.

Authors:  Davida M Schiff; Erin C Work; Bridget Foley; Rachel Applewhite; Hafsatou Diop; Latisha Goullaud; Munish Gupta; Bettina B Hoeppner; Elizabeth Peacock-Chambers; Corrie L Vilsaint; Judith A Bernstein; Allison S Bryant
Journal:  Pediatrics       Date:  2022-03-01       Impact factor: 9.703

6.  Caring for pregnant opioid abusers in Vermont: A potential model for non-urban areas.

Authors:  Marjorie Meyer; Julie Phillips
Journal:  Prev Med       Date:  2015-07-26       Impact factor: 4.018

7.  Maintenance agonist treatments for opiate-dependent pregnant women.

Authors:  Silvia Minozzi; Laura Amato; Shayesteh Jahanfar; Cristina Bellisario; Marica Ferri; Marina Davoli
Journal:  Cochrane Database Syst Rev       Date:  2020-11-09

8.  Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Childhood Outcomes: Executive Summary of a Joint Workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, American College of Obstetricians and Gynecologists, American Academy of Pediatrics, Society for Maternal-Fetal Medicine, Centers for Disease Control and Prevention, and the March of Dimes Foundation.

Authors:  Uma M Reddy; Jonathan M Davis; Zhaoxia Ren; Michael F Greene
Journal:  Obstet Gynecol       Date:  2017-07       Impact factor: 7.623

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.